Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21)

The summary for the Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21): This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental translational research (R21). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, and pesticides. The scope of the research includes target/candidate identification and characterization, through candidate optimization, and demonstration of in vivo efficacy. Projects supported by this FOA are expected to generate preliminary preclinical, screening, and/or efficacy data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.

Federal Grant Title:	Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Environment Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-15-315
Type of Funding:	Grant
CFDA Numbers:	93.113, 93.846, 93.853, 93.865, 93.867
CFDA Descriptions:	Environmental Health; Arthritis, Musculoskeletal and Skin Diseases Research; Extramural Research Programs in the Neurosciences and Neurological Disorders; Child Health and Human Development Extramural Research; Vision Research
Current Application Deadline:	Jan 30, 2018
Original Application Deadline:	Jan 30, 2018
Posted Date:	Jul 30, 2015
Creation Date:	Jul 30, 2015
Archive Date:	Mar 2, 2018
Total Program Funding:
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: For profit organizations other than small businesses
Private institutions of higher education
Small businesses
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
County governments
Public and State controlled institutions of higher education
Independent school districts
City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Special district governments
Public housing authorities/Indian housing authorities
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-15-315.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Sch...; • Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial...; • Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Cli...; • Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training...; • Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional); • Outstanding New Environmental Scientist Award (ONES); • Environmental Health Sciences Core Center Grants; • Leiomyomata Uteri: Basic Science and Translational Research
More Grants from the National Institutes of Health: • Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 ...; • Limited Competition: Research Centers in Minority Institutions (RCMI) Coordinating Center ...; • BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in th...; • NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required...; • Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 ...